Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Status: closed to accrual

A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation

Men or women greater than or equal to 18 years old.
ECOG ≤ 1
Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through central testing or have documentation of KRAS p.G12C mutation through Amgen Study 20190294 prior to enrollment

Active brain metastases
Myocardial infarction within 6 months of study day 1
Gastrointestinal (GI) tract disease causing the inability to take oral medication

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04303780.

State:

Emory University Hospital/Winship Cancer Institute

Status: Active

Name Not Available

University of Michigan Rogel Cancer Center

Status: Active

Name Not Available

M D Anderson Cancer Center

Status: Active

Name Not Available

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Use the checklist in our guide to gather the information you’ll need.

Description